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Abstract
Background: The aim of the study was to detect whether in experimental Salmonella enterica
Typhimurium infection the probiotic Lactobacillus fermentum ME-3 in combination with
fluoroquinolone therapy would eradicate S. Typhimurium, prevent the development of liver and
spleen granulomas and improve the indices of oxidative stress in the ileum mucosa.
The selected bacteriological, histological and biochemical methods were applied.
Results:  Combined treatment with L. fermentum ME-3 and ofloxacin eradicated Salmonella
Typhimurium from blood, ileum and liver, decreased the number of animals with liver and spleen
granulomas and reduced the value of lipid peroxides in the ileum mucosa. Higher total counts of
intestinal lactobacilli in all experimental groups were associated with the absence of liver
granulomas.
Conclusion: The antimicrobial and antioxidative probiotic L. fermentum ME-3 combined with
ofloxacin enhances the eradication of experimental S. Typhimurium infection. These observations
on probiotic and antimicrobial co-action may serve as basis to develop new strategies for treatment
of invasive bacterial infections of the gut.
Background
Typhoid fever is a systemic infection caused by Salmonella
enterica serotype Typhi with 22 million of new cases regis-
tered annually worldwide despite various vaccination pro-
grams [1,2]. The prevalence of hepatobiliar system
involvement is considered in 1–26% of patients with
typhoid fever [3].
Broad-spectrum fluoroquinolones are the drugs of choice
for the treatment of typhoid fever [2] inhibiting even fas-
tidious intracellular pathogens in therapeutic concentra-
tions readily achievable in body fluids and tissues [4].
Despite the antimicrobial treatment almost 1–6% of
infected patients become chronic carriers [1] shedding
bacteria in their stools and urine for a varying period of
time.
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One possibility to devise new strategies in treatment of
bacterial gastrointestinal infections seems to be the appli-
cation of probiotics as an adjunct to chemotherapy. Pro-
biotic strains are defined as live microorganisms which,
when consumed in appropriate amounts in the food, con-
fer a health benefit on the host [5]. A number of clinical
trials with controversial results have been performed with
probiotics in the prevention and treatment of gastrointes-
tinal infections, caused by rotavirus and Clostridium diffi-
cile  [6-8]. In the management of Helicobacter pylori
infection probiotics in combination with antibiotic treat-
ment have been reported to be successful [9-11].
We applied a new probiotic Lactobacillus fermentum ME-3,
DSM 14241 (ME-3) [12] with high antimicrobial activity,
particularly against gram negative pathogens [12,13].
Besides, ME-3 has considerable resistance to several reac-
tive oxygen species (ROS) and possesses substantial anti-
oxidative activity demonstrated by expression of
manganese superoxide dismutase [14].
For experimental investigation of Salmonella Typhi infec-
tion a mouse model is reliable and it has been successfully
applied also in earlier studies [15,16]. The infection due to
S.  enterica  serotype Typhimurium in mice resembles
human typhoid fever with extra-intestinal granulomatous
lesions in different organs [2,17,18].
The aim of the current study was to detect whether in
experimental S. Typhimurium infection the probiotic ME-
3 in combination with fluoroquinolone therapy would
eradicate S. Typhimurium from host, prevent the develop-
ment of liver and spleen granulomas and improve the
indices of oxidative stress in the ileum mucosa.
Results
In vitro tests
The MIC values of ofloxacin (OFX) to S. Typhimurium
were 0.19 μg/ml and to ME-3 8 μg/ml. When the S. Typh-
imurium and ME-3 were tested together a six-fold
decrease in the MIC of OFX from 0.19 to 0.032 μg/ml was
observed with both applied methods (overlay and broth
dilution).
Experimental infection
All but two animals from S. Typhimurium group (Gr1)
survived up to the end of the experiment. The survival rate
in Gr1 was 91% and in other groups 100% on Day 10. As
demonstrated in Table 1 by Day 10 in Gr1 mice, chal-
lenged with S. Typhimurium, the viable bacteria were iso-
lated from the ileum, blood and the liver (11/20, 3/20
and 11/20, respectively). The administration of OFX
(Gr2) and ME-3 (Gr3) significantly reduced the number
of mice with viable S. Typhimurium in the ileum (p =
0.0032). Besides, S. Typhimurium was still cultivated
from blood and liver of some animals of Gr2 and Gr3.
While, viable S. Typhimurium were not found in any of
investigated sites applying the combination of OFX and
ME-3 (Gr4).
The frequent histopathological findings were the granulo-
mas in liver and spleen, detected in more than half of the
untreated animals (Gr1). In the spleen (Table 1) the treat-
ment with OFX as single and in combination with ME-3
were superior to treatment by ME-3 alone (both p =
0.048). The number of mice with liver granulomas was
significantly reduced by application of the OFX and ME-3
combination as compared to OFX alone (15% vs 62%, p
= 0.023).
Lactobacilli were present in terminal ileum of all investi-
gated animals (median counts 8.6 log10 CFU/g). Numer-
ous colonies of L. fermentum as species were detected in
animals of Gr3 and Gr4. However, we could not distin-
guish the presence of the strain L. fermentum ME-3. A
somewhat increased count and smaller variation of lacto-
bacilli was detected in groups of animals treated with L.
fermentum  ME-3 (Gr3 and Gr4 mice: range 8.7–9.6
median 9.1 vs Gr 1 and 2: 6.8–8.8 median 7.7). No trans-
location of lactobacilli into blood and liver was detected.
In all experimental groups the higher total counts of intes-
Table 1: The number of mice with viable S. Typhimurium and 
granulomas in liver and spleen
Experimental groups Number (%) of mice with
Salmonella Typhimurium Granulomas
ileum blood liver liver spleen
Gr1 (ST) 111;2 31 1 3 164;5 117
n = 20 55% 15% 55% 80% 55%
Gr2 (ST+OFX) 21 13 8 6 07;8
n = 13 15% 8% 23% 62%
Gr3 (ST+ME-3) 21 01 3 54 48
n = 13 15% 8% 38% 31%
Gr4 (ST+OFX+ME-3) 02 00 2 5;6 07;8
n = 13 15%
ST – Salmonella Typhimurium
OFX – ofloxacin
ME-3 – Lactobacillus fermentum ME-3
1 p = 0.032 Gr1 vs Gr2 and Gr3 viable ST in ileum
2 p = 0.002 Gr1 vs Gr4 viable ST in ileum
3 p = 0.009 Gr1 vs Gr3 viable ST in liver
4 p = 0.027 Gr1 vs Gr3 liver granulomas
5 p < 0.001 Gr1 vs Gr4 liver granulomas
6 p = 0.023 Gr2 vs Gr4 liver granulomas
7 p = 0.002 Gr1 vs Gr2 and Gr4 spleen granulomas
8 p = 0.048 Gr2 vs Gr3 and Gr4 vs Gr3 spleen granulomasBMC Microbiology 2008, 8:132 http://www.biomedcentral.com/1471-2180/8/132
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tinal lactobacilli were associated with the absence of gran-
ulomas in the liver (p = 0.002).
The indices of oxidative stress e.g. the level of LPO and
GSSG/GSH were higher in mice challenged with S. Typh-
imurium as compared to control group (p < 0.001 and p
< 0.003 respectively) (Table 2). The LPO values were
reduced significantly (p = 0.002) in both treatments: with
ME-3 alone (Gr3) and in combination with OFX (Gr4) as
compared with that of OFX (Gr2).
Discussion
We have previously shown that ME-3 has antagonistic
activity against S. enterica serovar Typhimurium as well as
in vitro [13] and in vivo mice model [16].
In this experimental study we explored the influence of
combined per oral treatment with OFX and L. fermentum
ME-3 to S. Typhimurium infection. The infection mimics
human typhoid fever characterised by specific granuloma-
tous lesions in various organs [3]. In the current study the
granulomas were detected in liver and spleen of S. Typh-
imurium challenged mice.
Although according to in vitro tests S. Typhimurium strain
was susceptible to OFX, the treatment did not eradicate S.
Typhimurium from ileum, blood and liver. By contrast,
OFX combined with probiotic ME-3 completely eradi-
cated viable S. Typhimurium from investigated sites and
prevented the formation of spleen granulomas, at the
same time significantly reducing the presence of liver
granulomas. To the best of our knowledge, this is the first
time that a Lactobacillus probiotic in combination with a
fluoroquinolone has been shown to exert beneficial effect
on the treatment of infectious granulomatous inflamma-
tion.
We observed an interesting difference between spleen and
liver in the prevention of the granulomas during combi-
native therapy of S. Typhimurium infection: the number
of mice with liver granulomas was higher than the corre-
sponding data of spleen. Obviously, this is due to the
more expressed immune-competence of spleen as com-
pared to liver.
The limitation of our study was that we did not differenti-
ate between the L. fermentum ME-3 strain and any indige-
nous Lactobacillus strains present in the mice gut during
the experiment. However, under the combinative treat-
ment with L. fermentum ME-3 and ofloxacin besides the
eradication of viable S.  Typhimurium the significant
reduction of granulomas in liver and their total absence in
spleen was found.
Concerning the application of probiotics in gastrointesti-
nal infections, the exact mechanism of action is not
known yet. Four possible mechanisms can be suggested.
First, it has been shown that lactobacilli produce several
substances like antimicrobials, lactic and non-lactic acids,
hydrogen peroxide which enables to inhibit or kill patho-
gens [19]. Second, in the gut lactobacilli seemingly com-
pete with the pathogen for the adhesion sites and
nutritional sources [6]. Third, lactobacilli usually cause
the immune-modulation of the host increasing the resist-
ance against pathogens and fourth, they are able to inhibit
the production of bacterial toxins [20]. All abovemen-
tioned factors seemingly might be involved in the eradica-
tion of Salmonella Typhimurium infection.
In the mice model the L. fermentum ME-3 apparently sup-
pressed Salmonella Typhimurium due to previously estab-
lished high antimicrobial activity and production of both
lactic and acetic acids and generation of H2O2 [13]. This
was in accordance with the current in vitro tests, where
MIC values of OFX to S. Typhimurium in combination
with ME-3 decreased even six-fold.
Remarkably, in mice with high numbers of intestinal
lactobacilli the granulomas of liver and spleen were not
found. Probably the increased counts of total lactobacilli
inhibited the spread of S. Typhimurium into organs and
prevented the formation of granulomas. This could have
been associated with hyperplasia of lymph nodes in
ileum, found previously after administration of ME-3 [16]
and involved also in the present study. (data not shown)
The absence of translocation of S.  Typhimurium and
intestinal lactobacilli as much as the reduced invasion of
S. Typhimurium into tested organs could be explained by
Table 2: Indices of oxidative stress (with standard deviations) in 
the ileum mucosa in mice challenged with S. Typhimurium and 
treated with ofloxacin and/or the probiotic L. fermentum ME-3
Experimental groups LPO (pmol/mg protein) GSSG/GSH
Gr1 (ST) 338 ± 461;4 0.26 ± 0.413;5
Gr2 (ST+OFX) 228 ± 412 0.26 ± 0.11
Gr3 (ST+ME-3) 169 ± 111;2 0.16 ± 0.203
Gr4 (ST+OFX+ME-3) 161 ± 271;2 0.17 ± 0.113
Control (PBS) 157 ± 244 0.11 ± 0.25
ST – Salmonella Typhimurium
OFX – ofloxacin
ME-3 – Lactobacillus fermentum ME-3
PBS – phosphate buffered saline
LPO – lipid peroxides
GSSG/GSH – glutathione redox ratio
1p < 0.001 Gr1 vs Gr3 and Gr4
2p = 0.002 Gr2 vs Gr3 and Gr 4
3 p = 0.006 Gr1 vs Gr3 and Gr4
4p < 0.001 Gr1 vs Control
5p < 0.003 Gr1 vs ControlBMC Microbiology 2008, 8:132 http://www.biomedcentral.com/1471-2180/8/132
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improved anti-oxidative status of gut mucosa. During the
intracellular infection phagocytes produce reactive oxygen
species (ROS), important for killing the pathogen.
Though the formation of ROS is reported to be induced
also by fluoroquinolones, their role in the antibacterial
action is not clearly understood [21]. The excessive
amounts of ROS damage the collateral intestinal epithe-
lial cells and the superoxide compound was responsible
for the generation of the granulomatous lesions limiting
the spread of infection [22]. In the current study it was
shown that the administration of this antioxidative probi-
otic to infected mice significantly reduced LPO values of
ileum mucosa in comparison with the gut of the untreated
and treated with OFX animals. Thus, the application of L.
fermentum ME-3 suppressed the excessive oxidative stress
indices and could have improved the oxidative state of the
gut mucosal tissue. Apparently, the neutralisation of the
produced superoxides by superoxide dismutase of ME-3
was one of the putative mechanisms in prevention of the
granulomatous lesions [14]. Recently, the concept of oxi-
dative stress has been advanced as "a disruption of redox
signalling and control" [23]. This emphasises the impact
of glutathione and its redox ratio in intestinal cells during
S. Typhimurium infection [16]. In the current study the
addition of ME-3 to OFX reduced glutathione redox ratio
by improving the oxidative status in ileum.
Conclusion
We conclude that the antimicrobial and antioxidative pro-
biotic  L. fermentum ME-3 combined with ofloxacin
enhances the eradication of experimental S. Typhimu-
rium infection. These observations on probiotic and anti-
microbial co-action could serve as basis to develop new
strategies for treatment of invasive bacterial infections of
the gut.
Methods
Bacterial strains and susceptibility testing
A clinical isolate of Salmonella enterica serovar Typhimu-
rium was kindly provided by the Estonian Laboratory of
Public Health Inspectorate.
For treatment of the experimental S. Typhimurium infec-
tion a fluoroquinolone ofloxacin (Hoechst, Germany)
and a probiotic L. fermentum ME-3 were applied. The MIC
values of ofloxacin to S. Typhimurium on Mueller-Hinton
media (Oxoid, UK) were measured by the E-test following
the manufacturer's instructions (AB Biodisk, Sweden) and
estimated according to the CLSI guidelines [24]. Lactoba-
cillus fermentum ME-3 originated from the Microbial
strains collection of Department of Microbiology of Uni-
versity Tartu.
The following two tests were used to evaluate the combi-
native effect of OFX and ME-3 against S. Typhimurium.
First, in the overlay test, 10 ml of the MRS agar (Oxoid,
UK), containing 108 CFU/ml of ME-3, was poured onto
agar plates and incubated in 10% CO2 at 37°C for 48 h.
Then the plates were overlaid with 5 ml 1.0% (w/w) Iso-
sensitest agar (Oxoid, UK) and 108 CFU/ml of S. Typh-
imurium was seeded into agar. Plates were incubated in
microaerobic conditions at 37°C for 24 h and E-test was
applied. Second, in the dilution test, serial two-fold dilu-
tions of OFX in broth were prepared. S. Typhimurium and
ME-3 solutions were adjusted to the 0.5 McFarland tur-
bidity standards and 10 μl of the suspension was placed
into the OFX broth (Nutrient broth No2 Oxoid, UK) and
the MBC values were detected. All susceptibility tests were
performed in duplicate.
Experimental murine model
The 4 to 6 week old NIH line mice (Kuopio, Finland) were
inoculated orally by a single 0.5 ml dose of the S. Typh-
imurium suspension (105 CFU/ml) using a sterile syringe
with the blunt-ended tube. After 48 hours animals were
treated either with OFX or ME-3 alone or with their com-
bination for 8 days. Control animals received PBS (phos-
phate buffered saline). OFX at doses of 20 mg/kg [25] was
diluted in 0.5 ml of PBS and given by the sterile syringe
with the blunt-ended tube once daily.
Lyophilised ME-3 (Probiotical s.r.l, Novara, Italy) was sus-
pended in PBS to a final concentration of 5 × 107CFU/ml.
During the experiments each mouse consumed daily
approximately 5 millilitres of ME-3 containing PBS,
receiving 2.5 × 108 CFU of lactobacilli.
The commercial diet R-70 (Lactamin, Sweden) with tap
water was given ad libitum.
A total of 61 mice were infected with S. Typhimurium and
divided into following groups: Gr1 (untreated; n = 22),
Gr2 (treated with OFX; n = 13), Gr3 (treated with ME-3; n
= 13) and Gr 4 (treated with OFX and ME-3; n = 13). In
addition, 11 uninfected animals were treated with PBS
and served as a control group for the biochemistry testing.
On Day 10 all the surviving animals were sacrificed by cer-
vical dislocation and an autopsy was performed. All exper-
iments were approved by the Committee of Animal
Experiments of Estonian Ministry of Agriculture.
Bacteriological assays
At autopsy 10 μl of the heart blood was cultured onto
McConkey agar (Oxoid, UK) and on the de Man-Rogosa-
Sharpe (MRS) medium (Oxoid, UK) for detection of S.
Typhimurium and L. fermentum, respectively. The samples
of the ileum and liver were homogenized with sterile glass
powder and 10 μl of homogenate was cultured onto
McConkey agar. All plates were incubated in the air at
37°C for 24 h. For quantification of lactobacilli theBMC Microbiology 2008, 8:132 http://www.biomedcentral.com/1471-2180/8/132
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homogenised samples from liver and ileum were weighed
and 10 μl of serial ten-fold dilutions in PBS (pH 7.2) were
cultured on the MRS and incubated in the 10% CO2 at
37°C for 48 h. The total counts of lactobacilli were calcu-
lated as CFU/mg. The lower limit of detection was ≥ 3.0
log CFU/ml. For identification of Lactobacillus fermentum
ME-3 the following criteria were applied: colony mor-
phology on MRS, negative catalase reaction, growth on
15°C, lysozyme production and gas production from glu-
cose [26].
Histology
Samples from the ileum, liver and spleen were fixed in
10% formaldehyde and processed further for paraffin
embedding. Tissue sections were stained by haematoxylin
and eosin. Two pathologists independently in a blinded
manner using coded slides evaluated inflammatory and/
or destructive lesions. The focal collections of inflamma-
tory cells with various degrees of necrosis were defined as
granulomas [27].
Biochemistry
The ileum mucosa collected at autopsy was stored at -
80°C until further analysis for a maximum of three
months. The indices of oxidative stress: LPO (lipid perox-
ides) and GSSG/GSH (glutathione redox ratio) were
measured after homogenization in a 1.15% KCL solution
(1:10).
The levels of LPO were detected using the commercial kit
Bioxytech LPO-586 (Oxis International, USA). The value
of the redox status of the ileum mucosa was expressed as
the glutathione redox ratio GSSG/GSH. The total glutath-
ione TSSG and the oxidized glutathione GSSG of the
ileum mucosa were measured using the Griffith method
[16,28]. Glutathione content was determined on the basis
of a standard curve generated with a known concentration
of this substance. The amount of reduced glutathione
GSH was calculated as the difference between TSSG and
GSSG.
Statistics
The computer program Sigma Stat for Windows 2.0 (Jan-
del Corporation, USA) was applied. The tests were
selected according to data distribution: the Fisher exact
test in comparing categorical values, the Student t-test
with Bonferroni correction for describing the continuous
indices. The Mann-Whitney test was used for comparing
unevenly distributed data.
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